Early clinical experience with imipenem-cilistatin

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Bacterial infections pose a significant clinical challenge.
• The need for effective broad-spectrum antibiotics remains high.
• Imipenem-cilistatin is an antibiotic formulation with potential against diverse bacterial pathogens.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of imipenem-cilistatin.
• To assess the microbiological cure rates of imipenem-cilistatin in patients with bacterial infections.
• To determine the spectrum of activity of imipenem-cilistatin against common bacterial isolates.

Main Methods:

• A prospective study involving 15 patients with 16 bacterial infections.
• Treatment administered with imipenem-cilistatin.
• Minimum Inhibitory Concentrations (MICs) determined for bacterial isolates.
• Infection types included respiratory tract, urinary tract, and other infections.
• Clinical and microbiological outcomes were assessed.

Main Results:

• Twelve out of 16 infections (75%) achieved microbiological cure.
• Bacterial isolates included Gram-positive cocci and Gram-negative bacilli.
• All isolates demonstrated MICs less than or equal to 2.0 mg/l.
• No significant drug side effects or toxicity were observed in patients.
• The formulation was well-tolerated across the patient cohort.

Conclusions:

• Imipenem-cilistatin demonstrated significant efficacy in treating a range of bacterial infections.
• The antibiotic exhibited a favorable safety profile with minimal adverse events.
• The study supports imipenem-cilistatin as a potentially valuable therapeutic option for bacterial infections.